Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

INFORM2 NivEnt: the First Trial of the INFORM2 Biomarker Driven Phase I/II Trial Series: the Combination of Nivolumab and Entinostat in Children and Adolescents with Refractory High-Risk Malignancies

Cornelis M. van Tilburg,Ruth Witt,Melanie Heiss,Kristian W. Pajtler,Christoph Plass,Isabel Poschke,Michael Platten,Inga Harting,Oliver Sedlaczek,Angelika Freitag, David Meyrath,Lenka Taylor,Gnana Prakash Balasubramanian,Natalie Jäger,Elke Pfaff,Barbara C. Jones,Till Milde,Stefan M. Pfister,David T. W. Jones,Annette Kopp-Schneider,Olaf Witt

BMC Cancer（2020）

Cited 28|Views118
Key words
Entinostat,Nivolumab,Child,Bayesian design,Biomarker,Phase I/II,Checkpoint inhibition,HDAC
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined